Crusader Energy Group Inc.
http://www.crusaderenergy.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Crusader Energy Group Inc.
Alexion On Its AstraZeneca Integration And Growth Plan
Two years after being acquired by AstraZeneca, the company remains relatively autonomous in rare disease, but with “bridges” to its big pharma parent.
Asia Deal Watch: Rona Takes On Sanofi’s siRNA Platform
Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.
China Biotech CEO Podcast: CANbridge’s Xue On Orphan Drug Coverage, Financing, Gene Therapy
While many of his peers elbowed each other to leap into oncology, James Xue decided to focus on rare diseases such as Hunter’s Syndrome. Now, 10 years after founding CANbridge, the CEO sat down for an audio interview with Scrip to offer his views on a flurry of key issues impacting orphan drug development in potentially the world's largest pharma market.
Addiction Therapies Inc.
Positing substance addiction as a memory disease, Addiction Therapies Inc. seeks to address both its chemical and behavioral components. Initially targeting nicotine, alcohol and cocaine addiction, ATI will combine novel therapeutics drugs with proprietary dosing strategies in a platform designed to actively engage addicts in their own recovery.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice